“FIB-4 ≥1.3 is correlated with increased DKD risk in T2D, but SGLT2i therapy that lowers FIB-4 attenuates this ” (2025) Diabzen, 3(4), pp. 120–127. Available at: https://www.thediabzen.com/index.php/d/article/view/34 (Accessed: 14 April 2026).